Publisher: HCP Live

Anaphylaxis recognition criteria have not been updated to reflect infant-specific presentations, even as newer international definitions already incorporate them.

Reframing when caregivers reach for epinephrine and expanding stock epinephrine access could meaningfully reduce delayed treatment in infants and toddlers with anaphylaxis, according to Jay Lieberman, MD, professor at the University of Tennessee Health Science Center and program director of the Allergy/Immunology Fellowship Program at Le Bonheur Children’s Hospital.

New reviews outline barriers to epinephrine use and support age-specific anaphylaxis recognition criteria in infants and toddlers, says Jay Lieberman, MD.

This 4-part special report examines persistent unmet needs and evolving best practices in anaphylaxis care, drawing on expert discussions from HCPLive, Contemporary Pediatrics, and Patient Care.

The CRL cited deficiencies limited to packaging and administration, with resubmission expected as early as Q3 2026.

Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.

At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, the HCPLive editorial team sat down with Tejesh Patel, MD/MBBS, about his portion of the session at RAD titled ‘Dose Flexibility in Adult Atopic Dermatitis.’

“I am reassured by the speed of symptom relief seen in the OAS study and by the continued and consistent rapid absorption profile of Anaphylm,” Jay Lieberman, MD, a professor of medicine in the department of pediatrics at the University of Tennessee Health Science Center, said in a statement. “These data provide strong evidence that… Read More